Fredun plans January CAT launch and nationwide hormonal rollout
Key highlights
- Fredun plans to launch CAT in about 60 to 90 days, or around January 2027.
- Fredun said its hormonal-products line is in the launch phase and will be sold across the country.
- Daulcél anti-ageing products are expected in metros within about 6 to 18 months.
- New-age businesses contributed almost 30% to 40% of Fredun’s second-quarter growth, according to management.
powered by IRIS

Fredun Pharmaceuticals Limited said CAT is planned for launch in about 60 to 90 days, or around January 2027, while its hormonal products are in the launch phase for nationwide distribution and Daulcél anti-ageing products are expected to reach metros in about six to 18 months.
Know Fredun Pharmaceuticals inside out
Results, valuation, peers and who's buying, in one view.
What products is Fredun preparing to launch?
Fredun is preparing three product programmes: CAT, a hormonal-products line and Daulcél, its anti-ageing line. Management placed CAT’s launch in about 60 to 90 days, said hormonal products were in the launch phase, and gave Daulcél the longest commercial timetable, at six to 18 months for availability across various metros.
The programmes have different planned market coverage. Fredun said hormonal products would be sold across the country, while Daulcél would first be introduced in metros and then potentially move to tier-two cities. CAT was described as a business on which management is “banking,” but the call did not define the CAT abbreviation or disclose its product categories.
When will Fredun launch CAT products?
Fredun said CAT would launch in about 60 to 90 days from the call, which management placed practically around January 2027. This is the shortest specific timetable among the three programmes and precedes the six-to-18-month window stated for Daulcél’s metro rollout.
Management also said Fredun was anticipating and pushing what it called a “phenomenally big” first CAT order. That remains an expectation rather than a reported order because the company did not disclose an order value, customer, product mix, quantity or the period in which related revenue could be recognised.
An analyst said there could be updates on the CATICO division over the next six to eight months and expressed hope that its brands could reach 80% to 90% of Indian counters within one year. Fredun management did not confirm that estimate as a company target, so the call provides no management-issued distribution target for CAT or CATICO.
How will Fredun distribute hormonal products nationwide?
Fredun said its hormonal products are in the launch phase, with goods being stocked for sales across the country. Management said it has a segment-specific product list and channels for the line, but did not identify the products, pricing, stocking volume, distributor base or number of sales outlets.
Management described the planned go-to-market route as an innovative channel and said Fredun was among the first in India to create channels of this kind for hormonal products. That is management’s description of the approach, while the call did not explain the channel mechanism or quantify participating doctors, pharmacies, distributors or other points of sale.
The nationwide hormonal plan differs from Daulcél’s geographic sequencing. Fredun intends hormonal products to be sold throughout India, whereas Daulcél is expected to enter metros first and only later potentially extend to tier-two cities. The company therefore disclosed separate distribution and rollout paths for the two product lines.
Got a follow-up? Ask IRIS
When will Daulcél anti-ageing products reach the market?
Fredun said Daulcél is its anti-ageing line and that products should be visible in the market across various metros in about six to 18 months. Management added that it hopes to enter tier-two cities after the metro stage, making expansion beyond metros conditional on the earlier rollout.
Management said Fredun has held certain dermaceutical licences for many years and described itself as the first company in India to obtain some of them. It also said doctors in relevant pockets know the company and are waiting for the products, but gave no count of licences, doctors, metros or expected sales.
Daulcél’s market timetable is later than CAT’s planned January 2027 launch and less immediately national than the hormonal rollout. The six-to-18-month range leaves a 12-month spread between the earliest and latest stated metro-market outcomes, so the speed of the line’s availability remains unresolved.
What operating backdrop did Fredun describe for these launches?
Fredun said new-age businesses supplied almost 30% to 40% of second-quarter growth, with Pet Care territories, mobility territories and functional-food orders contributing. Management contrasted this with the first quarter, when it said the vintage formulations business made a substantially larger contribution to growth.
The company said its earlier annual run-rate, or ARR, projections for Pet Care and mobility were in line and could be overachieved. Management also said the overall trend could outperform earlier projections by another 15% to 20% during the year, while declining to disclose absolute ARR figures.
Management referred to divisions that were operating at, or expected to operate at, ARR levels of Rs 60 crore, Rs 85 crore and Rs 100 crore. These were broad examples without identification of the divisions involved, so they do not establish revenue, ARR or sales targets for CAT, hormonal products or Daulcél.
Fredun also discussed Wagr, its Pet Care platform, which management said had a 45-person team after one year of operation. Management described Wagr as a broader Pet Care ecosystem rather than only an e-commerce platform and set out a five-to-six-year ecosystem-building plan separate from the CAT, hormonal and anti-ageing launches.
Conclusion
Fredun has set three distinct product timetables: CAT is planned in about 60 to 90 days, or around January 2027; hormonal products are being stocked for nationwide sales; and Daulcél is expected to reach metros over six to 18 months. The stated sequencing puts nationwide hormonal distribution ahead of Daulcél’s metro-first expansion, while CAT has the nearest dated launch indication.
The next disclosed milestones are whether CAT launches on the January 2027 timetable, how the nationwide hormonal channel is implemented and how quickly Daulcél appears across metros. Management’s six-to-18-month window for Daulcél, together with its plan to consider tier-two cities after metros, remains the main unresolved part of the rollout schedule.


